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Abstract
Background: A recent trial unexpectedly reported that atrial fibrillation, when defined as serious, occurred more often in
participants randomized to an annual infusion of the relatively new parenteral bisphosphonate, zoledronic acid, than
among those given placebo, but had limited power. Two subsequent population-based case-control studies of patients
receiving a more established oral bisphosphonate, alendronic acid, reported conflicting results, possibly due to uncontrolled
confounding factors.
Methodology/Principal Findings: We used the United Kingdom General Practice Research Database to assess the risk of
atrial fibrillation and flutter in women exposed to the oral bisphosphonates, alendronic acid and risedronate sodium. The
self-controlled case-series method was used to minimise the potential for confounding. The age-adjusted incidence rate
ratio for atrial fibrillation or flutter in individuals during their exposure to these oral bisphosphonates (n=2195) was 1.07
(95% CI 0.94–1.21). The age-adjusted incidence rate ratio for alendronic acid (n=1489) and risedronate sodium (n=649)
exposed individuals were 1.09 (95% CI 0.93–1.26) and 0.99 (95% CI 0.78–1.26) respectively. In post-hoc analyses, an increased
risk of incident atrial fibrillation or flutter was detected for patients during their first few months of alendronic acid therapy.
Conclusions/Significance: We found no robust evidence of an overall long-term increased risk of atrial fibrillation or flutter
associated with continued exposure to the oral bisphosphonates, alendronic acid and risedronate sodium. A possible signal
for an increase in risk during the first few months of therapy with alendronic acid needs to be re-assessed in additional
studies.
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Introduction
Oral bisphosphonates are effective in the prevention of
osteoporotic fractures.[1] However, a recent large international
randomized trial (HORIZON study) unexpectedly reported that
serious (defined as fatal, life-threatening or resulting in hospital-
ization or disability) atrial fibrillation (AF) occurred more
frequently in participants randomized to an annual infusion of
zoledronic acid than among those given placebo (1.3% vs. 0.5%;
p,0.001) raising concerns that AF may be an unexpected adverse
effect of zoledronic acid treatment specifically, or of bisphospho-
nate therapy in general.[2] Re-analysis of a previous trial also
reported a ‘trend’ towards an increased risk of serious AF events
among patients treated with oral alendronic acid compared with
placebo (1.5% vs. 1.0%; p=0.07) [3] and a recent population-
based case-control study found that ‘ever-use’ of oral alendronic
acid was associated with an increased risk of incident AF (odds
ratio 1.86; 95% confidence interval [CI], 1.09–3.15).[4] However,
these data conflict with results from other studies. For example,
earlier placebo-controlled trials, one of zoledronic acid and one of
risedronate sodium, found no excess risk of AF.[5] Moreover,
another recently published population-based case-control study
found no evidence that use of oral bisphosphonates increases the
risk of AF and atrial flutter.[6]
Although evidence from randomized trials is less likely to be
biased, the trials were not designed, or powered, to detect
differences in the risk of AF. Case-control studies have better
power but are prone to the effects of confounding. For example,
osteoporosis affects older people who are at higher risk of AF and
risk factors for AF, such as hyperthyroidism, also increase the risk
of osteoporosis.[1] Therefore people prescribed and not prescribed
bisphosphonates may well differ in terms of risk of AF, and these
differences are likely to cause bias and confounding in observa-
tional studies. Thus considerable uncertainty remains and these
concerns have led to a recent Europe-wide review of bisphospho-
nates and AF, including review of clinical trial data, spontaneous
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literature. As a result, it was recently announced that product
information for the intravenous bisphosphonates, zoledronic acid
and pamidronic acid, will be updated to include AF as a possible
side-effect.[7] The risk of AF with alendronic acid is to remain
under close scrutiny.[7]
We studied the association between oral bisphosphonates and
AF and atrial flutter in women using the self-controlled case-series
method [8,9] on routinely collected information from the large
United Kingdom (UK) General Practice Research Database
(GPRD). This approach provides information on an appropriately
large scale, using routine clinical data while minimizing the biases
that may affect case-control studies.
Methods
Participants
The GPRD is the world’s largest computerized database of
anonymized longitudinal medical records from primary care.
Currently data are being collected on over 3.6 million patients
from around 450 primary care practices throughout the UK.[10]
Female patients exposed to oral alendronic acid (10mg daily or
70mg weekly) or risedronate sodium (5mg daily or 35mg weekly)
between 1
st December 2004 and 31
st December 2006 were
included in the study. This comprised almost 400,000 person-years
of observations from 187 general practices.
Eligible participants were those who had a first-ever recorded
diagnosis of AF or atrial flutter within a pre-defined study window.
Medical diagnoses in the GPRD are recorded using OXMIS
(Oxford Medical Information Systems) and Read codes. OXMIS
codes are based on the International Classification of Diseases
(ICD) and Office of Population and Census Statistics (OPCS)
operation codes. Read codes became the standard for diagnostic
classification in the GPRD during 1998 so both codes were utilized
in this study. Both arrhythmias were coded separately (14 codes)
with the exception of two codes where they were combined. We
therefore studied AF and atrial flutter as one composite endpoint.
Nevertheless, most cases were probably AF as a previous study of
patients recorded in a Danish National Registry with an incident
diagnosis of AF or atrial flutter, showed that only 5% had pure
atrial flutter.[11] Study start dates were derived using the latter of
the individual practice’s up-to-standard date (GPRD-defined
quality marker based on assessment of completeness, continuity
and plausibility of data recording in key areas) or the patient’s first
registration date. Study end dates were derived using the
minimum of the patient’s transfer out date or the practice’s last
collection date.
If patients had recently (within 6 weeks) consulted their general
practitioner before their diagnosed event with symptoms that
could possibly indicate an arrhythmia, such as palpitations, their
date of onset was altered to the date of first symptom. Similarly, if
drugs such as digoxin were initiated within 6 weeks prior to the
incident arrhythmic event, the date of event was altered
accordingly.
Individuals were excluded if they had received cardiac
glycosides, amiodarone, sotalol, verapamil, diltiazem or a
cardioversion more than 6 weeks prior to their event because it
suggested that the arrhythmia may not be a new event. Cases were
also excluded if their medical records indicated that the
arrhythmia was likely to have been retrospectively recorded. For
example, if the patients AF or atrial flutter was recorded along
with other diagnoses on the day of a ‘new-patient’ or ‘well-person’
screen. We also excluded people whose only diagnostic entry for
their event appeared when the general practice received a post-
mortem report because we were concerned that the date recorded
would not accurately reflect the date of the arrhythmia.
Approval for our study was given by the Medicines and
Healthcare Regulatory Agency (MHRA) Independent Scientific
Advisory Committee (ISAC) for Database Research.
Procedures
We used the self-controlled case-series method which relies on
intra-person comparisons in a population of exposed individuals
who have had the outcome of interest. Incidence rate ratios (IRR)
of the outcome of interest are derived comparing defined intervals
during exposure relative to all other observed time periods for
each person.[8,9,12–15]
The start of the exposed period was defined as the date of first
bisphosphonate prescription. The end of the exposed period was
defined as the date of the last prescription plus the final
prescription quantity. A 30-day wash-out period was then added
to the end of the exposure date to ensure significant drug
elimination and to account for delays in obtaining prescriptions
and pharmacy supplies. All other observation time within the
study window was taken as the baseline (unexposed) period.
Participants included had a least one prescription (exposure) for a
bisphosphonate and at least one recorded episode of AF or atrial
flutter (event). Figure 1 illustrates a single individual who had a
Figure 1. Pictorial representation of the self-controlled case-series method using total exposure time to define the ‘risk’ period.
doi:10.1371/journal.pone.0004720.g001
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the exposed and baseline periods will usually vary for each
participant.
Statistical analysis
We controlled for age using ten, five-year, age bands (45–
49 years, 50–54, 55–59 etc.). IRR and 95% CIs were calculated
for incident events occurring within each stratum of the exposed
period compared to baseline periods using the aforementioned
case-series method. Sub-group analyses for alendronic acid and
risedronate sodium exposed individuals were planned a priori. Data
were analysed with Stata (version 9.0; StataCorp LP, College Station,
TX, USA).
Results
40,253 female patients exposed to oral bisphosphonates were
identified from the database, 3335 of whom were known to have
had at least one recorded episode of either AF or atrial flutter.
Figure 2 illustrates the derivation of the final study population that
were eligible for analysis (n=2195). The median age of women in
the study was 82 years (interquartile range [IQR] 76–86) and the
median total observation period (comprising in excess of 25,000
person-years) and exposure periods were 12.8 years (IQR 7.8–
16.5) and 23.1 months (IQR 7.7–41.7) respectively. After
controlling for age, the adjusted IRR for AF or atrial flutter was
1.07 (95% CI 0.94–1.21).
We conducted sub-group analyses, specified a priori, for
alendronic acid (n=1489) and risedronate sodium (n=649)
exposed patients. Fifty-seven patients who had received both
therapies were excluded. The calculated age-adjusted IRR for AF
or atrial flutter was 1.09 (95% CI 0.93–1.26) and 0.99 (95% CI
0.78–1.26) for individuals exposed to alendronic acid and
risedronate sodium respectively (see Table 1). In addition, we
undertook post-hoc time-to-event analyses (see Figure 3) in order to
determine if the risk of AF or atrial flutter differed by time after
initiation of treatment (see Table 2). A signal for an increased risk
of incident AF or atrial flutter was detected for patients during
their first few months of alendronic acid therapy (see Figure 4) and
no risk window was observed for risedronate sodium (see Figure 5).
We also conducted sensitivity analyses by increasing the wash-
out period to two and three months. In addition, we also excluded
patients whose observation period ended within one month of
their event in case observation censoring, due to events such as
death, biased the results. These sensitivity analyses yielded no
material change in the point estimate for alendronic acid or
risedronate sodium.
As a test of the robustness of the null result in relation to the
overall risk of AF or atrial flutter, we also examined the risk of
upper gastrointestinal problems, such as oesophagitis, in individ-
uals exposed to alendronic acid (n=5017), within the first three
Figure 2. Flow-diagram indicating derivation of bisphospho-
nate study population.
doi:10.1371/journal.pone.0004720.g002
Table 1. Risk of incident atrial fibrillation or flutter during exposure to the oral bisphosphonates, alendronic acid and risedronate
sodium.
N n (baseline) n (exposed) IRR 95% CI
Total bisphosphonate population 2195 1457 738 1.07 0.94–1.21
Alendronic acid exposed individuals 1489 960 529 1.09 0.93–1.26
Risedronate sodium exposed individuals 649 474 175 0.99 0.78–1.26
N=number or participants; n=number of events; IRR=incidence rate ratio; CI=confidence interval
doi:10.1371/journal.pone.0004720.t001
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effect of alendronic acid treatment. Exposure to alendronic acid
was associated with an increase in the risk of upper gastrointestinal
symptoms (IRR=1.26; 95% CI 1.04–1.51) which is in-keeping
with other real life observational data relating to alendronic acid
and upper gastrointestinal problems.[16]
Discussion
We report the largest observational study to date investigating
the association of oral bisphosphonates and AF involving over two
thousand exposed patients with one or more recorded episodes of
AF or atrial flutter. We found no evidence of an overall long-term
increased risk of AF or atrial flutter associated with alendronic acid
or risedronate sodium. However we could not exclude a small
increase in risk of arrhythmia during the first few months of
alendronic acid therapy. This apparent signal of an increased risk
should be interpreted with caution because we had reduced
statistical power to detect increases in risk over short time-frames
in this analysis. Moreover, as there are no established biological
mechanisms that might link bisphosphonate therapy to cardiac
arrhythmia, it is also difficult to know if this signal of an increased
risk soon after initiation of therapy has biological plausibility. In
the HORIZON trial, the risk of AF was distributed uniformly over
time, with the vast majority of events occurring more than 30 days
after infusion, by which time zoledronic acid is undetectable in the
Figure 3. Time-to-event analysis using pre-defined ‘risk’ periods after commencement of therapy.
doi:10.1371/journal.pone.0004720.g003
Table 2. Risk of incident atrial fibrillation or flutter after initiation of bisphosphonate therapy.
Post bisphosphonate initiation ‘risk’ period n (exposed) n (baseline) IRR 95% CI
2–4 weeks 16 2179 1.20 0.73–1.98
4–8 weeks 35 2160 1.39 0.99–1.96
8–12 weeks 31 2164 1.20 0.83–1.74
12–26 weeks 89 2106 1.11 0.89–1.39
26–52 weeks 121 2074 0.97 0.80–1.17
52–104 weeks 177 2018 0.94 0.80–1.11
Post alendronic acid initiation ‘risk’ period n (exposed) n (baseline) IRR 95% CI
2–4 weeks 11 1478 1.18 0.65–2.17
4–8 weeks 27 1462 1.58 1.07–2.33
8–12 weeks 22 1467 1.27 0.82–1.97
12–26 weeks 58 1431 1.05 0.80–1.38
26–52 weeks 91 1398 1.06 0.85–1.32
52–104 weeks 133 1356 1.02 0.84–1.23
Post risedronate sodium initiation ‘risk’ period n (exposed) n (baseline) IRR 95% CI
2–4 weeks 4 645 1.06 0.39–2.84
4–8 weeks 7 642 0.92 0.43–1.97
8–12 weeks 8 641 1.13 0.55–2.28
12–26 weeks 29 620 1.26 0.85–1.87
26–52 weeks 26 623 0.73 0.49–1.09
52–104 weeks 41 608 0.82 0.59–1.15
n=number of events; IRR=incidence rate ratio; CI=confidence interval.
doi:10.1371/journal.pone.0004720.t002
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doi:10.1371/journal.pone.0004720.g004
Figure 5. Risk estimates of incident atrial fibrillation or flutter after initiation of risedronate sodium.
doi:10.1371/journal.pone.0004720.g005
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to AF, but the administration of zoledronic acid had little or no
effect on serum calcium levels measured 9 to 11 days after
infusion.[2]
One major limitation of research using routinely collected
clinical data is the robustness of the recording information,
although diagnostic codes for AF have been validated within the
GPRD with over 95% of cases confirmed by a questionnaire.[17]
However a recent study indicated that many primary care
professionals cannot accurately detect AF on an electrocardio-
gram.[18] Though we used AF/atrial flutter as a combined end-
point, other European Registry data suggest that 95% of these
cases are likely to be AF.[11]
Certain other important limitations also need to be borne in
mind. First, secondary care prescriptions are unavailable from the
sampling frame and this may have introduced a small degree of
error in ascertaining the start of some exposure periods. In addition,
we assumed that all patients actually took their medication as
prescribed which is unlikely, especially for prophylactic medicines.
Second, as in any study based on clinical identification of AF, there
may have been a delay between onset of the arrhythmia, clinical
presentation, confirmation of diagnosis and recording in GPRD.
This could possibly have produced a bias towards the null, but
would be unlikely to have obscured entirely a clinically meaningful
effect. Third, our study which utilized anonymized patient data was
unabletodistinguishmore‘serious’episodesofAFasreportedinthe
randomized trial data. Fourth, data pertaining to other oral
bisphosphonates, such as disodium etidronate and ibandronic acid,
were not available in our supplied data set therefore these results are
not directly applicable to these agents.
However, there were also several strengths to the approach we
used and were also able to detect an increase in the risk of upper
gastrointestinal problems, which is an established adverse effect of
alendronic acid therapy in routine clinical practice. Research using
the GPRD has the great advantage of its large size which means
that we were able to include many more cases of AF in
bisphosphonate exposed individuals than previous studies. Our
data are consistent with the larger of the two recently published
conflicting population-based studies which included 435 and 47
exposed patients with AF respectively [4,6] and is in-keeping with
a recent re-analysis of a large placebo controlled trial involving
risedronate sodium.[5] The self-controlled case-series method we
used also helps minimize confounding and other biases inherent in
the more widely-used research designs in pharmacovigilance.
Case-control studies can be very successful in identifying adverse
effects from a new treatment where the risk is large, and the
adverse effect being studied is otherwise rare in the group being
treated. The risk of phocomelia from thalidomide exposure is one
such example. However, detecting a small increase in the risk of an
adverse event that is common among the patient group receiving a
new treatment can be more challenging. AF is common among the
elderly population who are the major users of bisphosphonate
treatment and a non-causal association between bisphosphonate
treatment and AF could arise by confounding because several risk
factors for osteoporosis and AF are shared; and osteoporosis may
itself be a risk factor for cardiovascular disease.[1] In this situation,
the size of the error introduced by confounding could be similar in
magnitude to the risk of the adverse effect. Biases and confounding
are minimized in randomized trials but these are usually designed
and powered as trials of efficacy, which means that there are often
only few recorded adverse events in any one trial. This can lead to
considerable uncertainty around the risk estimates derived. In
contrast, the self-controlled case-series method has the advantage
that confounding is minimized by ensuring the comparisons are
intra-person. In other words, such an analysis removes the
variation between individuals in risk factors for cardiac disease
and thus fixed confounders are implicitly controlled for. Statistical
techniques can control for confounders in traditional observational
studies however these need to be known and measurable.
Including multiple variables also subjects the regression model to
the degree of uncertainty associated with each. Using recorded
blood pressure is one such example. The self-controlled case-series
method also requires only a sample of the cases (e.g. individuals
exposed to oral bisphosphonates with a recorded episode of AF or
atrial flutter), and thus avoids the need for selecting adequate
controls. A similar technique, known as the case-crossover,[19]
can also control for fixed confounders, however this method
requires the assumption that exposure distribution in successive
time periods is exchangeable.[20] The self-controlled case-series
method we utilized does not require such an assumption. In
particular, age or time effects can be allowed for in much the same
way as in a cohort study.[20] Finally, when applied to data sets
such as the GPRD, the risk information obtained relates to routine
clinical use of a drug and therefore has good external validity.
In conclusion, we found no evidence of an overall long-term
increased risk of AF or atrial flutter associated with the oral
bisphosphonates, alendronic acid and risedronate sodium. These
observational data, obtained using the self-controlled case-series
method, are larger in scale and less prone to confounding than
previous observational studies and provide reassurance that the
overall long-term risk of AF or atrial flutter with the chronic use of
alendronic acid and risedronate sodium is either very small or not
present at all. The signal we detected for a possible increased risk
during the first few months of alendronic acid therapy warrants
replication and further clarification to assess its robustness.
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